1.59
-0.01(-0.63%)
Currency In USD
| Previous Close | 1.6 |
| Open | 1.62 |
| Day High | 1.65 |
| Day Low | 1.55 |
| 52-Week High | 9.25 |
| 52-Week Low | 0.87 |
| Volume | 347,870 |
| Average Volume | 625,260 |
| Market Cap | 68.14M |
| PE | 0.39 |
| EPS | 4.09 |
| Moving Average 50 Days | 1.67 |
| Moving Average 200 Days | 2.75 |
| Change | -0.01 |
If you invested $1000 in Outlook Therapeutics, Inc. (OTLK) since IPO date, it would be worth $2.34 as of July 01, 2025 at a share price of $1.6. Whereas If you bought $1000 worth of Outlook Therapeutics, Inc. (OTLK) shares 5 years ago, it would be worth $62.5 as of July 01, 2025 at a share price of $1.6.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer
GlobeNewswire Inc.
4 hours ago
Well-established executive with over 20 years of experience building and leading commercial teams across diverse therapeutic markets and geographies Career focused on driving business growth and developing an integrated commercial strategy to deliver
Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event
GlobeNewswire Inc.
Jun 18, 2025 1:05 PM GMT
Live webcast on Wednesday, June 25th at 12:00 PM ETISELIN, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of
Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
GlobeNewswire Inc.
Jun 10, 2025 12:05 PM GMT
ISELIN, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the Scottish Medi